No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.3x · 10Y median 0.2x · 75th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 18
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:01:54.638Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:01:54.638Z. Latest historical point 2025-03-31. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:01:54.638Z. Latest historical point 2025-03-31. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:54.638Z. Latest historical point 2025-03-31. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:54.638Z. Latest historical point 2025-03-31. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Healthcare Triangle, Inc. (HCTI) stock was $0.58 as of Oct 6, 2026, 10:00 AM EDT, down 4.78% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -99.6% · 3-year avg -97.8%/yr
Healthcare Triangle, Inc. (HCTI) is a technology firm dedicated to the healthcare sector, specializing in crafting innovative solutions across cloud services, data science, and professional and managed IT support.
Medical - Healthcare Information Services · Pleasanton, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.97
Revenue Est.
$9.65M
Last Quarter Results
EPS
$-1.56
vs Estimate
$-3.43
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1HCTI | $8.65M | $0.58 | -4.78% | -99.61% | N/A | N/A | N/A |
| 2MEDS | $8.38M | $3.19 | -4.63% | -90.01% | -45.88% | -25.43% | vs HCTI |
| 3APRE | $8.23M | $0.67 | -1.57% | -54.79% | -63.30% | N/A | vs HCTI |
| 4ADVB | $9.18M | $6.64 | +4.73% | -31.85% | N/A | N/A | vs HCTI |
| 5ICU | $9.22M | $3.25 | -8.45% | -45.14% | N/A | N/A | vs HCTI |
| 6GTBP | $8.04M | $6.37 | +3.41% | -61.33% | -73.13% | -68.76% | vs HCTI |
forward FY estimate
N/A
$9.19M
vs Estimate
$10.35M
Consensus Rating
Based on 1 analyst
Average Price Target
$3.15
+445.1% upside
Low
$3.15
Current
$0.58
High
$3.15
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.97 | $-0.97 | $-0.97 | 1 |
| Quarter ending Dec 2026 | $-0.87 | $-0.87 | $-0.87 | 1 |
| Quarter ending Mar 2027 | $-5976.00 | $-5976.00 | $-5976.00 | 1 |
| Quarter ending Jun 2027 | $-5976.00 | $-5976.00 | $-5976.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-10.23 | $-10.23 | $-10.23 | 1 |
| FY 2027 | $-3.18 | $-3.18 | $-3.18 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $9.65M | $9.65M | $9.65M | 1 |
| Quarter ending Dec 2026 | $10.13M | $10.13M | $10.13M | 1 |
| Quarter ending Mar 2027 | $12.60M | $12.60M | $12.60M | 1 |
| Quarter ending Jun 2027 | $12.40M | $12.40M | $12.40M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $38.84M | $38.84M | $38.84M | 1 |
| FY 2027 | $40.54M | $40.54M | $40.54M | 1 |
